Inflammatory bone loss is caused by a complex pathway that begins with inflammatory cell production of cytokines, progresses to abnormal bone absorption, and culminates in the destruction of joints, bone fractures, and patient debility.
Inflammatory bone loss is caused by a complex pathway that begins with inflammatory cell production of cytokines, progresses to abnormal bone absorption, and culminates in the destruction of joints, bone fractures, and patient debility.
George Schett, MD, professor of internal medicine and rheumatology from Universitatsklinikum Erlanger, discussed the pathophysiology of bone loss at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
He began by noting that inflammation plays a significant role in body and bone homeostasis. A slight elevation of C-reactive protein (CRP), suggesting a small amount of inflammation, can increase a patient’s fracture risk. Therefore, patients with diseases that result in continuous inflammation have a much higher risk of fractures and loss of bone mass. Examples of these vulnerable patients include not only those with rheumatoid arthritis, osteoarthritis, and juvenile arthritis, but also patients with localized inflammation in one organ system like Crohn’s disease (gut inflammation) and patients with psoriasis (skin inflammation).
Dr Schett described patients suffering from chronic inflammatory diseases as “swimming in a sea of cytokines.” The path of inflammation-induced bone loss in rheumatoid arthritis begins when inflammatory cells produce large amounts of cytokines. Among other functions, cytokines encourage the activity of osteoclasts, resulting in increased bone absorption. As the osteoclasts accumulate, they dig tunnels underneath the cartilage, destroy joint architecture and debilitate patients.
Systemic inflammation associated with rheumatoid arthritis destroys cortical and trabecular bone structure. In order to stop the decline in bone mass, patients must be treated with anti-inflammatory medications to decrease cytokine levels. Cytokines decrease bone mass in a number of ways. Some, like TNF-alpha and IL-6, inhibit bone formation and suppress intrinsic repair mechanisms. Others, like B cells, interfere with the function of other cells
Therefore, cytokine blockers (such as TNF or IL-6 blockers) can end bone loss and also induce the repair of previous bone damage. Dr Schett noted that the development of targeted cytokine antibodies may lead to new modalities for bone repair in the future.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More